BioMérieux Nabs CE Mark for RT-PCR SARS-CoV-2, Influenza A/B Assay

Dec 16, 2020

|

NEW YORK – BioMérieux said on Wednesday that it has received CE marking for its SARS-COV-2 Respi R-Gene test, which tests for SAR-CoV-2 and other respiratory infections.

BioMérieux's new assay simultaneously detects SARS-CoV-2 and influenza viruses A and B. Within each test kit is a cellular control to check the quality of the sample, and the kit comes with a second real-time PCR analysis to detect human respiratory syncytial virus and human metapneumovirus.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

P.1 Re-infection Concerns

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

Aiming for May

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

NIH Program to Address Structural Racism

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Featured White Papers

Congenica Enables Five Minute Diagnosis of Previously Unsolved Case

Congenica CNV Calling for Exomes Whitepaper

Congenica Splice Site Finder White Paper

Expediting an Accurate Diagnosis through Streamlined Clinical Workflows

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

16

Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community.

Mar

17

Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Menu

BioMérieux Nabs CE Mark for RT-PCR SARS-CoV-2, Influenza A/B Assay

To read the full story....

Breaking News

Molecular Health Inks Agreement for Precision Medicine Tools With Falco Biosystems

Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs

Oppenheimer Initiates Coverage of MDxHealth at Outperform

Genomics plc Closes $30M Funding Round

Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

Aegea, Biocept Ink Supply Agreement for Coronavirus MDx Test

The Scan

P.1 Re-infection Concerns

Aiming for May

NIH Program to Address Structural Racism

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

Featured White Papers

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

What's Popular?

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

GenMark Diagnostics Seeing Continued Demand for Respiratory Panels, Plans 510(k) Submission

Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

Sponsorships